ALPS 6-K: SEC filing
Alps Group Inc
Filed with the SEC on · accession 0001493152-26-051236
ALPS filed a 6-K (foreign company report) with the SEC on Nov 12, 2026. How foreign companies listed in the US report news and events — like an 8-K for them. The stock moved +0.8% by the first close after the filing.
Summary of the filing
Alps Group Inc announced the launch of a Pharmaco-Interaction (PCI) laboratory unit within its MyGenome subsidiary, with CYP450 inhibitory IC50 testing as its first commercial service offering.
Key details
How ALPS stock reacted
Close before
$1.19
Nov 11, 2026
First close after
+0.84%
$1.20
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for ALPS, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for ALPS?
Click hereFrequently asked questions
What did ALPS file with the SEC on Nov 12, 2026?
ALPS filed a 6-K (SEC filing). Alps Group Inc announced the launch of a Pharmaco-Interaction (PCI) laboratory unit within its MyGenome subsidiary, with CYP450 inhibitory IC50 testing as its first commercial service offering.
How do I read a 6-K?
How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.
How did ALPS stock react to this filing?
ALPS closed at $1.19 before the filing and $1.20 on Nov 12, 2026 (+0.84%).
Other ALPS SEC filings
Get alerts when ALPS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days